Single-Dose HPV Vaccination: Fact sheet on Current Evidence

The World Health Organization’s (WHO) Strategic Advisory Group of Experts (SAGE) on Immunization concluded that a single dose of human papillomavirus (HPV) vaccine delivers solid protection against HPV. Based on the available evidence, SAGE advised that countries may now choose between a one- or two-dose schedule for 9–14-year-old girls and women aged 15 to 20. This is a major step toward reaching the WHO’s global strategy to accelerate the elimination of cervical cancer.

This two-page brief a snapshot of the evidence supporting WHO’s endorsement of a single-dose HPV vaccination schedule.

Visit the Single-Dose HPV Vaccine Evaluation Consortium page for additional resources.

Corporate author(s): PATH

Publication date: November 2023

Available materials

  1. English

    1. Single-Dose HPV Vaccination: High-Level Brief on Current Evidence 408.8 KB PDF

  2. French

    1. Vaccination contre le HPV à dose unique: note d’information de haut niveau sur les données probantes actuelles 402.4 KB PDF